Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 1761 • 2019 ACR/ARP Annual Meeting
The Prospective Open Label Preventive Approach to Congenital Heart Block with Hydroxychloroquine (PATCH) Study Demonstrates a Reduction in the Recurrence Rate of Advanced Block
Peter Izmirly¹, Mimi Kim ², Nathalie Costedoat-Chalumeau ³, Deborah Friedman ⁴, Amit Saxena ⁵, Joshua Copel ⁶, Rebecca Cohen ¹, Mala Masson ¹, Tishaun Middleton ¹, Kimberly Robins ¹, Robert Clancy ¹ and Jill Buyon ¹, ¹NYU School of Medicine, New York, ²Albert Einstein College of Medicine, Bronx, NY, ³Cochin University Hospital, Paris, France, ⁴New York Medical College, Valhalla, ⁵New York University School of Medicine, New York, NY, ⁶Yale School of Medicine, New Haven
Background/Purpose: Based on encouraging bench to bedside results including experimental evidence supporting Toll-like receptor signaling in the pathogenesis of CHB, a case control study demonstrating…
Abstract Number: 2025 • 2019 ACR/ARP Annual Meeting
Ancestry Influences the Gene Expression Profile in Systemic Lupus Erythematosus and Contributes to Transcriptomic Heterogeneity in Lupus Patients
Michelle Catalina¹, Prathyusha Bachali ², Anthony Yeo ³, Nicholas Geraci ², Michelle Petri ⁴, Amrie Grammer ² and Peter Lipsky ², ¹AMPEL BioSolutions, LLC, harvard, MA, ²AMPEL BioSolutions, LLC, Charlottesville, VA, ³Rilite Foundation, Charlottesville, VA, ⁴Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a complex autoimmune disease with both sex and ancestral bias. Gene expression analysis has revealed complex heterogeneity between SLE…
Abstract Number: 2285 • 2019 ACR/ARP Annual Meeting
Higher Than Expected Rates of Adverse Pregnancy Outcomes in Patients with Systemic Lupus Erythematosus from Three Tertiary Care Centers
Ashley Blaske¹, Amanda Eudy ², Katie Kirchoff ³, Jim Oates ⁴, Megan Clowse ² and April Barnado ¹, ¹Vanderbilt University Medical Center, Nashville, TN, ²Duke University, Durham, ³Medical University of South Carolina, Charleston, SC, ⁴Division of Rheumatology & Immunology/Medical University of South Carolina, Charleston, SC
Background/Purpose: Prospective cohort studies of pregnancies managed by experts demonstrate that up to 30% of systemic lupus erythematosus (SLE) pregnancies result in preterm birth. We…
Abstract Number: 2535 • 2019 ACR/ARP Annual Meeting
Identifying Subgroups of SLE Patients with Differential Responses to a BLyS Inhibitor: Application of a Machine Learning Algorithm to Clinical Trial Data
Mimi Kim¹, Kith Pradhan ¹, Peter Izmirly ², Kenneth Kalunian ³, Leslie Hanrahan ⁴ and Joan Merrill ⁵, ¹Albert Einstein College of Medicine, Bronx, NY, ²New York University School of Medicine, New York, ³University of California at San Diego, San Diego, ⁴Lupus Foundation of America, Washington DC, ⁵Oklahoma Medical Research Foundation, Oklahoma City
Background/Purpose: Given the heterogeneity of systemic lupus erythematosus (SLE), the effect of any intervention is expected to vary. The ability to identify those most and…
Abstract Number: 2735 • 2019 ACR/ARP Annual Meeting
Response Gene to Complement -32 Exerts Proinflammatory and Profibrotic Effects in Immune Complex Gediated Glomerulonephritis
Vinh Nguyen ¹, Alexandru Tatomir ², Horea Rus ³, Cinthia Drachenberg ¹, John Papdimitriou ¹, Tudor Badea ⁴, Irina Luzina ⁵ and Violeta Rus¹, ¹Univ of Maryland Sch of Medicine, Baltimore, MD, ²Univ of Maryland Sch of Medicine, Baltimore, ³Univ of Maryland Sch of Med and VAMHCS, Baltimore, MD, ⁴NIH, NEI, Bethesda, MD, ⁵Univ of Maryland Sch of Med AND VAMHCS, Baltimore
Background/Purpose: Response Gene to Complement (RGC)-32 is a cell cycle regulator widely expressed in normal tissues, multiple tumors and a variety of cell lines. RGC-32…
Abstract Number: 2867 • 2019 ACR/ARP Annual Meeting
Nocturnal Blood Pressure Dipping as a Marker of Endothelial and Cardiac Function in Pediatric-onset Systemic Lupus Erythematosus
Joyce Chang¹, Taylor Goldberg ¹, Sarah McGuire ¹, Lindsay Waqar ¹, Kevin Meyers ¹, Laura Mercer-Rosa ¹, Pamela F. Weiss ¹ and Andrea Knight ², ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²Division of Rheumatology, The Hospital for Sick Children, Department of Paediatrics, University of Toronto, Toronto, ON, Canada
Background/Purpose: There is a need for clinically useful measures of cardiovascular (CV) risk in pediatric-onset SLE (pSLE). Nocturnal blood pressure (BP) non-dipping (loss of the…
Abstract Number: 98 • 2019 ACR/ARP Annual Meeting
Selective Induction of Functional Regulatory T-Cells in Healthy Volunteers by NKTR-358, a Novel IL-2 Conjugate Treg Stimulator, in Development for the Treatment of Autoimmune Diseases
Christie Fanton¹, Neha Dixit ¹, Suresh Siddhanti ¹, Lin Lu ¹, Daniel Dickerson ², Brian Kotzin ¹ and Jonathan Zalevsky ¹, ¹Nektar Therapeutics, San Francisco, ²PRA Health Sciences, Lenexa
Background/Purpose: Regulatory T cell (Treg) dysfunction and impaired IL-2 production have been implicated as key immunological defects in multiple autoimmune diseases. Enhanced sensitivity of Tregs…
Abstract Number: 677 • 2019 ACR/ARP Annual Meeting
Performance of Montreal Cognitive Assessment (MoCA) in Screening for Cognitive Impairment in Patients with Lupus Compared to the Neuropsychological Battery
Mahta Kakvan ¹, Robin Green ², Lesley Ruttan ³, Maria Tartaglia ⁴, Joan Wither ⁵, Moe Zandy ¹, Dennisse Bonilla ¹, May Choi ⁶, Jiandong Su ¹, Marvin Fritzler ⁶, Dorcas Beaton ⁷ and Zahi Touma¹, ¹University Health Network, University of Toronto, Toronto, ON, Canada, ²University Health Network, Toronto, ON, Canada, ³Toronto Rehabilitation Institute, Toronto, Canada, ⁴University Health Network, University of Toronto, Toronto, ON, Canada, ⁵University Health Network, Krembil Research Institute, Toronto, ON, Canada, ⁶Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁷St. Michael's Hospital, Toronto, ON, Canada
Background/Purpose: Cognitive impairment (CI) is a common neuropsychological manifestation of Systemic Lupus Erythematosus (SLE) with a prevalence of 38% [95% confidence interval: 33,43%]. Previous studies,…
Abstract Number: 897 • 2019 ACR/ARP Annual Meeting
Mortality Rates After Coronary Revascularization Procedures Among Systemic Lupus Erythematosus Compared to Diabetes Mellitus and General Population Medicaid Patients
Medha Barbhaiya¹, Sarah Chen ², Candace Feldman ³, Hongshu Guan ³, Brendan Everett ⁴ and Karen Costenbader ⁴, ¹Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ²Brigham and Women's Hospital and Harvard Medical School, Boston, ³Brigham and Women's Hospital, Boston, ⁴Brigham and Women's Hospital, Boston, MA
Background/Purpose: Despite similar myocardial infarction risks in SLE and diabetes mellitus (DM) patients, individuals with SLE enrolled in Medicaid had substantially higher rates of coronary…
Abstract Number: 1097 • 2019 ACR/ARP Annual Meeting
Trends in NSAIDs and Opioids Among Patients with SLE: A Population-based Study
Lingyi Li¹, Na Lu ¹, Jacek Kopec ², John Esdaile ³, Hui Xie ⁴ and J. Antonio Avina-Zubieta ², ¹Arthritis Research Canada, Vancouver, BC, Canada, ²Arthritis Research Canada and the University of British Columbia, Vancouver, BC, Canada, ³Arthritis Research Canada and the University of British Columbia, Richmond, BC, Canada, ⁴Arthritis Research Canada and Simon Fraser University, Vancouver, BC, Canada
Background/Purpose: Non-steroidal anti-inflammatory drugs (NSAIDs) and opioids are prescribed for the management of pain among patients with rheumatic diseases including systemic lupus erythematosus (SLE). However,…
Abstract Number: 1562 • 2019 ACR/ARP Annual Meeting
The Association of Body Weight Fluctuation and All-Cause Mortality in Patients with Systemic Lupus Erythematosus
Sarah Bayefsky¹, Alyson Dickson ¹, Tyler Reese ¹, Jocelyn Gandelman ², Megan Shuey ¹, April Barnado ¹, Katherine Barker ¹, C. Michael Stein ¹, Vivian Kawai ¹ and Cecilia Chung ¹, ¹Vanderbilt University Medical Center, Nashville, TN, ²Vanderbilt University School of Medicine, Nashville, TN
Background/Purpose: Recent studies have suggested that body weight fluctuation in the general population is an independent risk factor for overall mortality. These findings are of…
Abstract Number: 1604 • 2019 ACR/ARP Annual Meeting
The Systemic Lupus Erythematosus Cardiovascular Risk Equation
Michelle Petri¹, Erik Barr ² and Laurence Magder ², ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²University of Maryland School of Medicine, Baltimore, MD
Background/Purpose: Accelerated atherosclerosis remains the major cause of late death (after 5 years) in systemic lupus erythematosus (SLE). Yet, the "traditional" cardiovascular risk equations (such…
Abstract Number: 1763 • 2019 ACR/ARP Annual Meeting
A Phase 3 Randomized Controlled Trial of Anifrolumab in Patients with Moderate to Severe Systemic Lupus Erythematosus
Richard Furie¹, Eric Morand ², Ian Bruce ³, Susan Manzi ⁴, Kenneth Kalunian ⁵, Edward Vital ⁶, Theresa Lawrence-Ford ⁷, Ramesh Gupta ⁸, Falk Hiepe ⁹, Mittermayer Santiago ¹⁰, Philip Brohawn ¹¹, Anna Berglind ¹² and Raj Tummala ¹³, ¹Zucker School of Medicine at Hofstra/Northwell, New York, NY, ²Monash University, Melbourne, Victoria, Australia, ³University of Manchester, Manchester, United Kingdom, Manchester, England, United Kingdom, ⁴Allegheny Health Network, Pittsburg, PA, ⁵Division of Rheumatology, Allergy, and Immunology, University of California San Diego, La Jolla, CA, ⁶University of Leeds, Leeds, United Kingdom, ⁷North Georgia Rheumatology, Lawrenceville, GA, ⁸Baptist Memorial Hospital-Memphis, Memphis, TN, ⁹Charité University Hospital Berlin, Berlin, Germany, ¹⁰Bahiana School of Medicine and Public Health, Bahia, Brazil, ¹¹AstraZeneca, Gaithersburg, MD, ¹²AstraZeneca, Gothenburg, Sweden, ¹³AstraZeneca, Gaithersburg, MD, USA, Gaithersburg, MD
Background/Purpose: In a phase 2 study in SLE patients (pts), substantial efficacy was observed with anifrolumab, a human monoclonal antibody that binds the type I…
Abstract Number: 2026 • 2019 ACR/ARP Annual Meeting
MicroRNA-27a Can Contribute to Interferon Signatures in Systemic Lupus Erythematosus via the Suppression of Tripartite Motif-containing Protein 27
Daiga Kishimoto¹, Ryusuke Yoshimi ¹, Yosuke Kunishita ¹, Yumiko Sugiyama ², Takaaki Komiya ¹, Natsuki Sakurai ³, Reikou Kamiyama ¹, Yohei Kirino ⁴ and Hideaki Nakajima ⁴, ¹Department of Stem Cell and Immune Regulation / Yokohama City University Graduate School of Medicine, Yokohama, Japan, ²Department of Rheumatic Diseases / Yokohama City University Medical Center, Yokohama, Japan, ³Department of Stem Cell and Immune Regulation / Yokohama City University Graduate School of Medicine, Yokohama City, Japan, ⁴Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan
Background/Purpose: Type Ⅰ interferons (IFN) contribute to antiviral innate immune responses. Upon viral infection, pattern recognition receptors trigger TANK-binding kinase 1 (TBK1) activation and lead…
Abstract Number: 2293 • 2019 ACR/ARP Annual Meeting
Pregnancy in Patients with Systemic Lupus Erythematosus After Cyclophosphamide Therapy
Mitali Sen¹, Anu Kurl ¹, Tejal Vashi ² and Arezou Khosroshahi ¹, ¹Emory University, Atlanta, GA, ²Emory University School of Medicine, Atlanta, GA
Background/Purpose: Systemic lupus erythematosus (SLE) predominantly affects females of reproductive age. Cyclophosphamide, an alkylating agent, labelled category D for pregnancy, is used for induction in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].